NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms

This publication has 113 references indexed in Scilit:

• Phthalimide analogs of CB 1954
  Anti-Cancer Drugs, 1999
• Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci
  Carcinogenesis: Integrative Cancer Research, 1999
• The redox-sensitive human antioxidant responsive element induces gene expression under low oxygen conditions
  Carcinogenesis: Integrative Cancer Research, 1998
• Indolequinone Antitumor Agents: Reductive Activation and Elimination from (5-Methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl Derivatives and Hypoxia-Selective Cytotoxicity in Vitro
  Journal of Medicinal Chemistry, 1998
• Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies
  Pharmacogenetics, 1997
• Gene Targeting of DT-Diaphorase in Mouse Embryonic Stem Cells: Establishment of Null Mutant and Its Mitomycin C-Resistance
  Biochemical and Biophysical Research Communications, 1995
• Mouse dioxin-inducible NAD(P)H
  Pharmacogenetics, 1994
• A refined physical map of the long arm of human chromosome 16
  Genomics, 1991
• Phenobarbital-induced cytosolic cytoprotective mechanisms that offset increases in NADPH cytochrome P450 reductase activity in menadione-mediated cytotoxicity1
  Toxicology and Applied Pharmacology, 1989
• On the mechanism of the Mn3+-induced neurotoxicity of dopamine: Prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase
  Chemico-Biological Interactions, 1989